
Femara
Letrozole
- SKU
- 0078-0249
- Mfr
- Novartis Pharmaceuticals Corporation
30 tablet, film coated in 1 bottle, plastic
$1,098.99
Price for one pack
Prescription required. Upload your prescription at checkout or email it to us after ordering. We ship once a pharmacist has checked it. How it works
Femara is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy.
- Strength
- Letrozole 2.5 mg/1
- Unit of measure
- Per 1 tablet
- Dosage form
- Tablet, Film Coated
- Route
- Oral
Pharmacologic class
- Aromatase InhibitorEstablished class
- Aromatase InhibitorsMechanism
- Brand name
- Femara
- Generic name
- Letrozole
- Manufacturer
- Novartis Pharmaceuticals Corporation
- Product NDC (SKU)
- 0078-0249
- Active ingredients
- Letrozole 2.5 mg/1
- Unit of measure
- Per 1 tablet
- Dosage form
- Tablet, Film Coated
- Route
- Oral
- DEA schedule
- Not controlled
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- NDA
- Application number
- NDA020726
- Marketed since
- July 31, 1997
- Label revised
- June 11, 2026
| Package NDC | Description |
|---|---|
| 0078-0249-15 | 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC |
Reading this NDC
0078-0249-15
- 01Labeler code
- Novartis Pharmaceuticals Corporation
- 02Product code
- Femara, tablet, film coated
- 03Package code
- 30 tablet, film coated in 1 bottle, plastic
The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents).
These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.
Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to estrogens. In adult nontumor- and tumor-bearing female animals, letrozole is as effective as ovariectomy in reducing uterine weight, elevating serum LH, and causing the regression of estrogen-dependent tumors. In contrast to ovariectomy, treatment with letrozole does not lead to an increase in serum FSH. Letrozole selectively inhibits gonadal steroidogenesis but has no significant effect on adrenal mineralocorticoid or glucocorticoid synthesis.
Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. Treatment of women with letrozole significantly lowers serum estrone, estradiol and estrone sulfate and has not been shown to significantly affect adrenal corticosteroid synthesis, aldosterone synthesis, or synthesis of thyroid hormones.
Femara is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy.
First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.
Adjuvant
Treatment of Early Breast Cancer Femara (letrozole) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
Extended Adjuvant
Treatment of Early Breast Cancer Femara is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of Femara in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival (DFS) in patients treated with Femara for a median of 60 months.
First and Second-Line
Treatment of Advanced Breast Cancer Femara is indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Read before you order

Women's health · 2 min read
The combined pill vs the progestogen-only pill
How combined and progestogen-only contraceptive pills differ, who each suits, the side effects and what to do about a missed pill.

Women's health · 2 min read
Menopause hormone therapy (HRT) explained
How HRT relieves hot flushes and other menopause symptoms, why a progestogen is needed, patches vs tablets and the risks in context.

Women's health · 1 min read
Clomiphene for fertility: how ovulation induction works
How clomiphene triggers ovulation, how a treatment cycle is timed and monitored, the chance of twins and the side effects.
More in Women's Health
View all
Brand · Tablet
Activella
Estradiol .5 mg/1, Norethindrone Acetate .1 mg/1
- SKU
- 60846-231
- Mfr
- Amneal Pharmaceuticals LLC
From $30.99Min. 10 packs

Brand · Tablet
Angeliq
Estradiol .5 mg/1, Drospirenone .25 mg/1
- SKU
- 50419-482
- Mfr
- Bayer HealthCare Pharmaceuticals Inc.
From $120.99Min. 3 packs

Generic · Tablet
Clomid
Clomiphene Citrate 50 mg/1
- SKU
- 0713-0885
- Mfr
- Cosette Pharmaceuticals, Inc.
From $224.99Min. 2 packs

Generic · Tablet
Clomid
Clomiphene Citrate 50 mg/1
- SKU
- 50090-6500
- Mfr
- A-S Medication Solutions
From $678.99